8V6 Stock Overview
Offers cancer care and pain management solutions in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Scandinavian ChemoTech AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.18 |
| 52 Week High | SEK 0.23 |
| 52 Week Low | SEK 0.039 |
| Beta | 1.45 |
| 1 Month Change | 132.19% |
| 3 Month Change | 224.72% |
| 1 Year Change | 13.92% |
| 3 Year Change | -84.59% |
| 5 Year Change | n/a |
| Change since IPO | -85.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8V6 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 112.6% | 1.5% | 2.5% |
| 1Y | 13.9% | -11.3% | 14.4% |
Return vs Industry: 8V6 exceeded the German Medical Equipment industry which returned -11.3% over the past year.
Return vs Market: 8V6 matched the German Market which returned 14.4% over the past year.
Price Volatility
| 8V6 volatility | |
|---|---|
| 8V6 Average Weekly Movement | 50.4% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 8V6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8V6's weekly volatility has increased from 35% to 50% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 4 | Stefan Frick | chemotech.se |
Scandinavian ChemoTech AB (publ) offers cancer care and pain management solutions in Sweden. The company offers IQWave, an electroporation device, used for electrochemotherapy and treatment of head and neck cancer, squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. It also offers Vetiqure for the treatment of superficial tumors in dogs, cats, and horses.
Scandinavian ChemoTech AB (publ) Fundamentals Summary
| 8V6 fundamental statistics | |
|---|---|
| Market cap | €4.74m |
| Earnings (TTM) | -€1.25m |
| Revenue (TTM) | €600.24k |
7.9x
P/S Ratio-3.8x
P/E RatioIs 8V6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8V6 income statement (TTM) | |
|---|---|
| Revenue | SEK 6.57m |
| Cost of Revenue | SEK 1.79m |
| Gross Profit | SEK 4.78m |
| Other Expenses | SEK 18.49m |
| Earnings | -SEK 13.72m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 06, 2025
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 72.75% |
| Net Profit Margin | -208.91% |
| Debt/Equity Ratio | 0% |
How did 8V6 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 01:25 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Scandinavian ChemoTech AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sebastian Andersson | Redeye |
| Martin Wahlstrom | Redeye |